Eagrán speisialta sa Bhulgáiris: Caibidil 11 Imleabhar 036 P. 201 - 203
Eagrán speisialta sa Rómáinis: Caibidil 11 Imleabhar 036 P. 201 - 203
Eagrán speisialta i gCróitis: Caibidil 11 Imleabhar 115 P. 197 - 199
English
Select your language
Official EU languages:
Access to European Union law
EUR-Lex
Access to European Union law
This document is an excerpt from the EUR-Lex website
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Need more search options? Use the
Advanced search
Document 32004R1876
Commission Regulation (EC) No 1876/2004 of 28 October 2004 amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines
Commission Regulation (EC) No 1876/2004 of 28 October 2004 amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines
Commission Regulation (EC) No 1876/2004 of 28 October 2004 amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines
IO L 326, 29.10.2004, p. 22–24
(ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV) Foilsíodh an doiciméad seo in eagrán speisialta
(BG, RO, HR)
IO L 183M, 5.7.2006, p. 280–282
(MT)
No longer in force, Date of end of validity: 12/06/2016; Arna aisghairm go hintuigthe ag 32016R0793
Language
HTML
PDF
Official Journal
|
29.10.2004 |
EN |
Official Journal of the European Union |
L 326/22 |
COMMISSION REGULATION (EC) No 1876/2004
of 28 October 2004
amending Annex I of Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines (1), and in particular Article 4(8) thereof,
Whereas:
|
(1) |
The Commission has received applications under Article 4 of Regulation (EC) No 953/2003 with respect to certain pharmaceutical products. |
|
(2) |
The Commission has determined that the applications received fulfil the requirements set out in Regulation (EC) No 953/2003 in accordance with the procedure laid down in Article 5(2) of that Regulation. |
|
(3) |
The applicants have been informed of the Commission decision to accept their applications. |
|
(4) |
It is therefore necessary to add the products concerned to Annex I to Regulation (EC) No 953/2003, |
HAS ADOPTED THIS REGULATION:
Article 1
The products and other details mentioned in the Annex to this Regulation shall be added to Annex I to Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines.
Article 2
This regulation enters into force on the day following its publication in the Official Journal of the European Union.
It shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 28 October 2004.
For the Commission
Pascal LAMY
Member of the Commission
ANNEX
|
Product |
Manufacturer/exporter |
Country of destination |
Distinctive features |
Date of approval |
CN/TARIC code (1) |
||||||
|
‘TRIZIVIR 750 mg × 60 |
|
Afghanistan Angola Armenia Azerbaijan Bangladesh Benin Bhutan Botswana Burkina Faso Burundi Cambodia Cameroon Cape Verde Central African Republic Chad Comoros Congo Côte d’Ivoire Djibouti DR Congo East Timor Equatorial Guinea Eritrea Ethiopia Gambia Ghana Guinea Guinea Bissau Haiti Honduras India Indonesia Kenya Kiribati Korea (Dem Rep) Kyrgyz Republic Lao People’s DR Lesotho Liberia Madagascar Malawi Maldives Mali Mauritania Moldova Mongolia Mozambique Myanmar Namibia Nepal Nicaragua Niger Nigeria Pakistan Rwanda Samoa Sao Tome and Principe Senegal Sierra Leone Solomon Islands |
Distinctive access pack — trilingual text |
19.4.2004 |
3004 90 19 |
||||||
|
EPIVIR 150 mg × 60 |
|
Distinctive access pack — trilingual text |
19.4.2004 |
3004 90 19 |
|||||||
|
RETROVIR 250 mg × 40 |
|
General export pack (blue) not used in EU French hospital pack — Francophone markets |
19.4.2004 |
3004 90 19 |
|||||||
|
RETROVIR 300 mg × 60 |
|
General export pack (blue) not used in EU French hospital pack — Francophone markets |
19.4.2004 |
3004 90 19 |
|||||||
|
RETROVIR 100 mg × 100 |
|
General export pack (blue) not used in EU French hospital pack — Francophone markets |
19.4.2004 |
3004 90 19 |
|||||||
|
COMBIVIR 300/150 mg × 60 |
|
Distinctive access pack — trilingual text Bottle (rather than blister pack) “A22” embossed tablets |
19.4.2004 |
3004 90 19 |
|||||||
|
EPIVIR ORAL SOLUTION 10 mg/ml 240 ml |
|
Distinctive access pack — trilingual text |
19.4.2004 |
3004 90 19 |
|||||||
|
ZIAGEN 300 mg × 60 |
|
Somalia South Africa Sudan Swaziland Tajikistan Tanzania Togo Tuvalu Uganda Vanuatu Yemen Zambia Zimbabwe |
General export pack — not used in EU French hospital pack — Francophone countries |
20.9.2004 |
3004 90 19 |
||||||
|
RETROVIR ORAL SOLUTION 10 mg/ml 200 ml |
|
Distinctive access pack — trilingual text |
20.9.2004 |
3004 90 19 |
(1) Only if applicable.’